Lv1
100 积分 2026-04-14 加入
Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study
1个月前
已完结
PARP Inhibitors Rechallenge in Patients With Recurrent Ovarian Cancer: A Multicentre Real‐World Study in China
1个月前
已完结
Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
1个月前
已完结
An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer
1个月前
已完结
Enhanced paclitaxel oral delivery by astragalus polysaccharide-based nanoplatform for triple-negative breast cancer treatment
1个月前
已完结
Nanoparticle Albumin-Bound Paclitaxel Is Superior to Liposomal Paclitaxel in The Neoadjuvant Treatment of Breast Cancer
1个月前
已完结
Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer
1个月前
已关闭
Nab-paclitaxel vs paclitaxel liposome for advanced breast cancer: real-world efficacy and safety analysis
1个月前
已完结
Integrative co-delivery platforms for paclitaxel: Advancing synergistic breast cancer therapy
1个月前
已关闭
Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review
3个月前
已完结
皖公网安备34019202002308
